Traders Purchase High Volume of Definium Therapeutics Call Options (NASDAQ:DFTX)

Definium Therapeutics, Inc. (NASDAQ:DFTX) saw some unusual options trading activity on Friday. Stock traders purchased 8,130 call options on the stock. This represents an increase of approximately 460% compared to the typical volume of 1,451 call options.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. BIT Capital GmbH purchased a new position in Definium Therapeutics during the third quarter worth about $26,000. Fifth Third Bancorp raised its holdings in Definium Therapeutics by 5,593.2% during the third quarter. Fifth Third Bancorp now owns 3,359 shares of the company’s stock worth $40,000 after purchasing an additional 3,300 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after purchasing an additional 2,003 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in Definium Therapeutics by 56.0% during the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after purchasing an additional 3,020 shares in the last quarter. Finally, Flagship Harbor Advisors LLC purchased a new position in Definium Therapeutics during the fourth quarter worth about $117,000. 27.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. Canaccord Genuity Group set a $38.00 price objective on shares of Definium Therapeutics and gave the company a “buy” rating in a research note on Thursday, April 16th. Leerink Partners upped their target price on shares of Definium Therapeutics from $23.00 to $30.00 and gave the company an “outperform” rating in a report on Wednesday, April 22nd. Piper Sandler reaffirmed an “overweight” rating and issued a $48.00 target price (down from $49.00) on shares of Definium Therapeutics in a report on Friday, May 8th. Wolfe Research assumed coverage on shares of Definium Therapeutics in a report on Monday, February 23rd. They issued an “outperform” rating and a $25.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definium Therapeutics in a report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $37.92.

Definium Therapeutics Price Performance

Shares of NASDAQ:DFTX opened at $24.75 on Friday. The company has a 50-day simple moving average of $22.32 and a 200-day simple moving average of $17.93. Definium Therapeutics has a one year low of $6.34 and a one year high of $26.25. The company has a debt-to-equity ratio of 0.15, a quick ratio of 4.69 and a current ratio of 4.69. The stock has a market capitalization of $2.47 billion, a price-to-earnings ratio of -9.94 and a beta of 2.37.

Definium Therapeutics (NASDAQ:DFTX) last announced its earnings results on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). On average, analysts predict that Definium Therapeutics will post -2.3 EPS for the current year.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.